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Biotin feeding in a Balb/c mouse model of breast cancer suggest that the tumor load is
~100% greater in biotin-deficient mice compared with biotin-sufficient controls, and that
the increase is associated with metastasis rather than new tumors. The oncogenes c-Myc
and COX-2 are implicated in cancer metastasis, and their expressions are repressed by
binding of MBP-1 to the promoter. Mass spectrometry studies, designed to discover
novel biotin-containing proteins, suggest that lysine residues K10 and K12 in the c-Myc
promoter binding protein (MBP-1) contains covalently bound biotin (MBP-1bio). We
hypothesized that biotinylation of MBP-1 increases the binding of MBP-1 to the c-Myc
and COX-2 promoter, thereby decreasing oncogene expression and metastasis. A novel
antibody against MBP-1bio was used to confirm the existence of MBP-1bio in human
mammary carcinoma MCF-7 cells; the abundance of MBP-1bio depended on the
concentration of biotin in culture media: supplemented > sufficient > deficient. The
activity of a c-Myc reporter gene was ~37% greater in biotin-deficient cells compared
with sufficient and supplemented controls. Likewise, both c-Myc and COX-2 mRNA
levels were significantly increased in deficient compared with sufficient cells. When K10
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and K12 in MBP-1 were removed by site-directed mutagenesis, biotin supply no longer
affected the expression of c-Myc and COX-2 in MCF-7 cells. Biotinylation of MBP-1 is
an enzymatic process catalyzed by using recombinant holocarboxylase synthetase
(HLCS), judged by using recombinant HLCS and recombinant MBP-1. Consistent with
this observation, c-Myc and COX-2 are de-repressed in HLCS mutant WG2215 human
fibroblasts compared with controls. We conclude that loss of MBP-1bio in biotindepleted and HLCS-deficient organisms leads to an increased expression of oncogenes,
thereby increasing cancer risk.
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Biotin, Holocarboxylase Synthetase (HLCS) and biotinylation

Biotin (C10H16N2O3S, MW: 244.31064), known as vitamin B7 or H, is a water-soluble
vitamin involved in epigenetic regulations and many metabolic pathways in mammals (17). Biotin is a monocarboxylic acid contains an ureido group, thiophane heterocyclic ring,
and a valeric acid side chain (7-9) (Fig. 1).

Figure 1. 2D structure of biotin (Pubchem CID 171548).
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Biotin is found in high concentration in varieties of foods including egg yolk, cow milk,
liver and some vegetables in the form of free biotin or biotin-binding protein conjugates
(10). For uptake of biotin from dietary resource, the biotin-binding proteins are converted
to free biotin by gastrointestinal proteases, peptidases, and biotinidase (7). The
fundamental metabolic role of biotinidase (BTD) is to hydrolyze biocytin generated in the
breakdown of biotin-binding carboxylases (11). Therefore, free biotin is released and
recycled in holocarboxylase synthesis and used as co-factor in epigenetic and metabolic
processes (9). The transportation of free biotin to the cells is depended on the sodiumdependent multi-vitamin transporter (SMVT) (12). It has been reported that
monocarboxylate transporter 1 (MCT1) is also involved in cellar biotin transportation in
peripheral blood mononuclear cells (11, 13, 14) (Fig. 2).

5

Figure 2. Biotin transport and metabolism, taken from (15). ACC1:
cytoplasmatic acetyl-CoA carboxylase alpha, ACC2: mitochondrial acetylCoA carboxylase beta, B: biotin, MCC: and 3- methylcrotonyl-CoA
carboxylase, MCT1: monocarboxylate transporter 1, PC: pyruvate
carboxylase, PCC: propionyl- CoA carboxylase, SMVT: sodium
multivitamin transporter.
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Holocarboxylase synthetase (HLCS), a 726 amino acids protein, is the sole biotin protein
ligase in the human proteome and is responsible for catalyzing biotinylation of acetylCoA caboxylase1 and 2 (ACC1, ACC2), 3-methylcrotonyl-CoA carboxylase (MCC),
pyruvate carboxylase (PCC) and propionyl-CoA carboxylase (PCC) and other proteins
(16). Biotinylated carboxylases are localized to cytoplasm and mitochondria and play
roles in intermediary metabolism including fatty acid synthesis, regulation of fatty acid
catabolism, elimination of odd-chain fatty acids, leucine metabolism, and
gluconeogenesis (1-3, 5, 6, 17, 18). HLCS also enters the nuclear compartment (2, 19-21).
Nuclear HLCS orchestrates the assembly of a multiprotein gene repression complex (22,
23). The formation of the multiprotein complex depends on the availability of biotin; the
complex appears to play an important roles in the repression of long terminal repeats
(LTRs), thereby contributing to genome stability (24). The covalent binding of biotin to
histones (1) appears to be a mere side effect of the close physical proximity of HLCS and
histones (22, 23)
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c-Myc promoter binding protein (MBP-1) and target
oncogenes of MBP-1 repression

c-Myc promoter binding protein (MBP-1, NCBI Reference Sequence: NM_001201483.1)
is a transcriptional variant encoded by ENO1 enolase 1, (alpha) [Homo sapiens](25)
(Gene ID: 2023). This MBP-1 protein consists of 341 amino acids is localized to the
nucleus that functions as a novel transcriptional repressor of oncogene c-Myc through
binding to the TATA box of its P2 promoter (26-28). In addition to c-Myc, MBP-1 also
represses the oncogenes cyclooxygenase-2 (COX-2) and ERBB2 (26, 29, 30). The MBP1 N-terminus is crucial for oncogene repression, which also involves accessory factors
such as activated Notch1 receptor, Kelch protein NS1-BP, and histone deacetylases (3134). C-Myc, COX-2, and ERBB2 are associated with tumorigenesis including breast and
gastric cancer, and low levels of MBP-1 have been observed in invasive ductal breast
carcinoma (IDC), which supporting the role of MBP-1 as a potential prognostic marker in
carcinoma (29, 35, 36).
c-Myc, Cox-2, and ERBB2 are examples of oncogenes regulated by MBP-1. c-Myc
dimerizes with Max; the heterodimer binds to E boxes in target genes and causes
aberrations in cell cycle, growth, apoptosis and metabolism (37-39) ( Fig. 3).
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Figure 3. Mechanisms of c-Myc involved in gene transcription, cell
growth and proliferation.
COX-2 is the inducible isoform of the COX-2/PTGS2 gene encoding prostaglandinendoperoxide synthase 2 (PTGS2, Gene ID: 5743), which is the key enzyme in
prostaglandin biosynthesis. High levels of COX-2 have been observed in tumor tissues
from a breast cancer mouse model housed in standard environment (40). Strong
associations between COX-2 and breast or gastric cancer have been established, COX-2
dependent activation of the p38/MAPK pathway (41), Jun N-terminal kinases mediated
activation of cell invasion in MCF-7 cells (42), and IL-1beta and NFkappaB mediated
induction of inflammation (43). COX-2 inhibitors such as celecoxib are considered
promising agents in the treatment and prevention of breast cancer (44, 45).
ERBB2 (Gene ID: 2064) encodes a member of the epidermal growth factor (EGF)
receptor family of receptor tyrosine kinases. High levels of ERBB2 have been observed
in metastatic breast cancer. ERBB2 contributes breast cancer metastasis through
increased expression of glutaminase 1(36), activation of NF-kappaB (46), and increased
breast cancer cell migration and invasion (47).
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In conclusion, MBP-1 is an important repressor of three oncogenes that play crucial roles
in tumorigenesis in human prostate, gastric and breast cancer.

CHAPTER 2
BIOTINYLATION OF THE C-MYC PROMOTER
BINDING PROTEIN MBP-1 DECREASES C-MYC
AND COX-2 EXPRESSION IN HUMAN
MAMMARY CARCINOMA MCF-7 CELLS

11
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Introduction
The c-Myc promoter binding protein, MBP-1, is encoded by the Enolase-1 gene and
consists of 341 amino acids. MBP-1 localizes in the cell nucleus and functions as a
transcriptional repressor of the oncogenes c-Myc, cyclooxygenase-2 (COX-2), and
ERBB2 (26-30, 48, 49). The N-terminus in MBP-1 is essential for repressor activity (31).
Repression may involve accessory factors such as Notch1 receptor (32), Kelch protein
NS1-BP (33), histone deacetylases (34), and miR-29b (50).
Recently, our discovery-based LC/MS/MS analysis identified MBP-1 as one of 108 novel
biotin-containing proteins in human embryonic kidney HEK293 cells (Li Y. et al.,
submitted). There is precedence that posttranslational modifications affect the activity of
transcription factors. For example, biotin supplementation decreases Sp1 and NF-κB
binding to their response elements (51); HLCS-dependent biotinylation of HSP72
increases RANTES expression(52). Importantly, at the time we had completed a biotin
feeding study in a murine breast cancer model, which suggested that the tumor load
increases by about 100% in biotin-deficient mice compared with biotin-sufficient and
biotin-supplemented mice (see Results). Based on the roles of MBP-1 in oncogene
repression, the detection of biotinylated MBP-1 by mass spectrometry, and the
observations in biotin feeding studies, we hypothesized that the binding of biotin to
MBP-1 increases oncogene repressor activity. We further hypothesized that biotinylation
of MBP-1 is mediated by the sole biotin protein ligase in the human proteome,
holocarboxylase synthetase (HLCS) (16).
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Materials and Methods
Cell cultures
Human embryonic kidney HEK293 cells (American Type Culture Collection, CRL-1573)
were cultured in Dulbecco's Modified Eagle Medium (DMEM) media containing 10%
fetal bovine serum, penicillin, streptomycin, and L-glutamine as described previously
(53).Human mammary carcinoma MCF-7 cells were cultured in DMEM/Nutrient F-12
Ham (DMEM/F12). In select experiments, MCF-7 cells were cultured in biotin-defined
DMEM, prepared as described previously (53). Biotin-defined media contained the
following levels of biotin: 0.025 nmol/L, 0.25 nmol/L, and 10 nmol/L, representing biotin
plasma levels observed in deficient, normal, and supplemented persons, respectively (11,
53, 54). HLCS-deficient WG2215 fibroblasts from an HLCS mutant patient (Montreal
Children’s Hospital Cell Repository, Montreal, Canada) and HLCS wild-type human
neonatal normal dermal fibroblast (American Type Culture Collection, PCS-201-010)
were cultured in Fibroblast Basal Medium supplemented with 2% fetal bovine serum, 5
ng/mL recombinant human fibroblast growth factor (rh FGF) beta, 5 µg/mL recombinant
human insulin, 1 µg/mL hydrocortisone, 50 µg/mL ascorbic acid, and 7.5 mM Lglutamine.

Purification of biotinylated proteins and mass spectrometry
analysis
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Whole protein extracts were prepared from HEK293 cells using ice-cold BugBuster®
Protein Extraction Reagent (Novagen, EMD Millipore), protease inhibitor cocktail
(Sigma). Biotin-containing proteins were purified using a Monomeric Avidin Agarose
following the manufacturer’s recommendations (Thermo Scientific; biotin-binding
capacity=1.2 mg biotinylated protein/mL settled resin) (Fig. 1).
Biotinylated proteins were resolved by gel electrophoresis and cut-out bands were
digested with trypsin (55). Biotinylated proteins and biotinylation sites were identified by
LC/MS/MS in the mass spectrometry core facility in the Redox Biology Center at the
University of Nebraska-Lincoln. The acquired spectrum was compared to the human
reference proteome for sequence identification using the MASCOT database analysis
software (56).

Plasmids and recombinant proteins
The c-Myc promoter luciferase reporter plasmid, Luc-SNM, includes base pairs -467 to
+36 in the human c-Myc gene and two MBP-1 binding sites (57); the plasmid was
generously provided by Dr. Mark D Minden in the Department of Cellular and Molecular
Biology, Ontario Cancer Institute, Toronto, Canada.
Full-length human MBP-1 (Genbank NM_001201483.1) was cloned using a human
enolase 1 (alpha) cDNA clone (MGC: 17252; IMAGE: 3447583) using forward primer
5’- TTCGGGTAG TGGAAAACCAG-3’ and reverse primer 5’- CAGCAGCTCGAATT
TCTTCC - 3’; the PCR product was ligated into vector pET28a+ (Novagen) using
FastDigest BamHI and SalI (Thermo Scientific), thereby creating plasmid
pET28a+_MBP-1 for preparing recombinant MBP-1. Recombinant his-tagged MBP-1
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was expressed and purified as described previously (1). Our previous studies suggest that
BirA in E. coli catalyzes the binding of biotin to some recombinant proteins (58);
biotinylated recombinant MBP-1 was removed by avidin chromatography (not shown).
Lysine residues K10 and K12 were identified as targets for biotinylation (see Results).
Site-directed mutagenesis was used to create a plasmid in which arginines were
substituted for K10 and K12. Mutant MBP-1 was created using MGC clone 17252, the
GeneTailorTM Site-Directed Mutagenesis System (Invitrogen), and primers
ATGGAACAGAAAATAGATCTAGGTTTG GTGCGAACGC and
GCGTTCGCACCAAACCTAGATCTATTTTCTGTTCCAT. The plasmid was denoted
ENO_Mut. The plasmid was digested with Fastdigest EcoRI and KpnI and ligated into
the p3XFLAG-Myc-CMVTM-26 expression vector (Sigma-Aldrich) to create plasmid
MBP-1R10,R12 coding for a Flag-tagged MBP-1protein.
Plasmid Flag-MBP-WT and MBP-1R10,R12 for expression of FLAG-tagged recombinant
wild-type and mutant MBP-1, respectively, were created as described for
pET28a+_MBP-1, using forward primer 5’- ACAGGCTTCCATTGACCAG -3’ and
reverse primer 5’- TCACCATAGAGTGCTTCCAAC - 3’. Plasmid C7472-CMV-7-BAP
codes for FLAG (Sigma-Aldrich) and was used as control.
GST-tagged recombinant full-length HLCS was prepared by using plasmid pET41a (+)HLCS as described previously (1). The identities of all plasmids were verified by
sequencing.
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Generation of Anti–MBP-1 Antibody and Dot-blot Assay
The following synthetic, MBP-1 based peptide was used to raise antibodies against MBP1, biotinylated at K10 and K12 (MBP-1bio), as described previously (3): acCZIEMDGTENK(bio)SK(bio)FGANA-NH2 (Cocalico Biologicals, Inc., PA).
Antibody specificity was assessed using dot blot analysis. Briefly, dilution series (1.5 ug,
0.75 ug and 0.375 ug) of the following peptides were spotted onto PVDF membranes, air
dried, and probed with anti-MBP-1bio and goat anti-rabbit IgG：synthetic K10, K12biotinylated MBP-1( MBP-1bio), synthetic unbiotinylated MBP-1, chemically
biotinylated bovine serum albumin (BSAbio), synthetic peptides mimicking K18- and
K8-biotinylated histones H3 (H3K18bio) and H4 (H4K8bio).

Western Blot Analysis
Proteins were extracted from MCF-7 cells as described above; equal amount of protein
(~30 μg) were resolved by gel electrophoresis, and transblots were probed with the
following antibodies at 4°C overnight: anti-MBP-1bio, anti-Anti-6X His tag (Origene)
and anti- GAPDH (Santa Cruz Biotechnology). Secondary antibodies and visualization
and quantification by infrared imaging were conducted as described previously (59).
Blots were revealed and quantitated by Odyssey Infrared Imaging System (LI-COR
Biosciences).
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In vitro biotinylation assay
His-tagged MBP-1 was incubated with GST-tagged HLCS as described previously (1).
Biotin bound to MBP-1 was probed using streptavidin (1). Anti-His and Coomassie Blue
were used to confirm equal loading.

Transfection and luciferase assay
These assays were conducted to assess whether mutation of K10 and K12 in MBP-1
disrupts the regulation of MBP-1 repressor activity by biotin supply. Briefly, MCF-7 cells
were with Flag-WT-MBP1, MBP-1R10,12R, or C7472-CMV-7-BAP (control) using
TurboFect (Thermo Scientific) following the manufacturer's instructions (about 2 μg
plasmid/1,000,000 cells). Forty-eight hours after transfection, the expression of c-Myc
and COX-2 were analyzed using qRT-PCR.
MCF-7 cells cultured in biotin-defined media were cotransfected with luciferase reporter
Luc-SNM (pGL2 basic vector as control) and beta-galactosidase internal control vector
using TurboFect (Thermo Scientific) following the manufacturer's instructions (about 2
μg plasmid/1,000,000 cells). Forty-eight hours after transfection, cells were harvested for
the quantification of luciferase and beta-Gal activities according to standard methods
(Promega). Luciferase activity was measured by subtracting machine background and
normalizing via beta-galactosidase activity. The results are the average of at least three
independent experiments.
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Real-Time PCR Analysis (qRT-PCR)
Total RNA was isolated from MCF-7 cells using the illustra RNAspin Mini Kit (GE
Healthcare Life Sciences) and reverse transcribed into cDNA using the ImProm-II™
Reverse Transcription System (Promega) following the manufacturer's protocol. The
abundance of transcripts coding for human c-Myc, COX-2, HLCS and GAPDH (control)
were quantified by using Power SYBR Green PCR Master Mix (Applied Biosystems)
and the following primers: human c-Myc, 5’- TTCGGGTAGTGGAAAACCAG -3’
(forward) and 5’-CAGCAGCTCGAATTTCT TCC -3’ (reverse); human COX-2, 5’ACAGGCTTCCATTGACCAG-3’ (forward), 5’- TCACCATAG AGTGCTTCCAAC-3’
(reverse); HLCS, 5’- TGAGACCTGATCCTTAACTTCC -3’ (forward) 5’ATGGAAGATAGACTC CACAT -3’ (reverse); GAPDH (control), 5’TCCACTGGCGTCT TCACC -3’ (forward), 5’- GGCAGAGAT GATGACCCTTT -3’
(reverse). Transcript abundance was quantified using the comparative threshold cycle (Ct)
method.

Statistical Analysis

Homogeneous variances were analyzed by using Bartlett’s test. Significance of
differences was tested by one-way ANOVA and the Fisher's Protected Least Significant
Difference (PLSD). For pairwise comparisons the t-test was used. StatView5.0.1 (SAS
Institute) was used to perform all calculations. Data were reported as mean ± SD.
Differences were considered significant if P < 0.05.
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Results
Discovery of novel biotinylated proteins in HEK293 cells
Analysis of protein extracts by LC/MS/MS revealed the identities of 108 novel
biotinylated proteins in human cells (Li Y. et al., in preparation), including biotinylation
of K10 and K12 in the N-terminus of MBP-1 (Fig. 1).
We raised anti-MBP-1bio to determine whether MBP-1bio is detectable in using western
blot analysis and to assess whether the abundance of MBP-1bio depends on the levels of
biotin in culture media. Anti-MBP-1bio produced a strong signal with peptide MBP-1bio,
but did not cross-react to a meaningful extent with unbiotinylated MBP-1, chemically
biotinylated bovine serum albumin (BSAbio), synthetic peptides mimicking K18- and
K8-biotinylated histones H3 (H3K18bio) and H4 (H4K8bio) (Fig. 2A). Pre-immune
serum produced negligible signal with biotinylated MBP-1 and other controls (Fig. 2B).
Equal loading was confirmed using Ponceau S stain as probe (not shown). The signal
intensity produced by MBP-1bio was about 40 times greater than that produced by
unbiotinylated MBP-1 (Fig. 2C). Pre-immune serum produced negligible signal
compared with anti-MBP1bio, when MCF7 cell extracts were assayed using western blot
analysis (Fig. 2D).
After 3 days of culture in biotin-defined media, the abundance of MBP-1bio in biotin
sufficient MCF-7 cells was increased, compared with that of deficient and physiological
cells (Fig. 3A). Compared with anti-MBP-1bio, pre-immune serum produced no signal.
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The efficacy of biotin treatment was confirmed using the abundance of bioitnylated
carboxylases as markers for biotin status (Fig. 3B).

Enzymatic biotinylation of MBP-1
HLCS is the sole enzyme responses for catalyzing covalent binding of biotin to proteins
in the human proteomics. To determine the biotin ligase activity of HLCS on MBP-1, the
in vitro biotinylation assay was conducted. His-MBP1 was biotinylated in a timedependent manner after incubated with GST-HLCS (Fig. 4) (52).

c-Myc and COX-2 expression depends on biotin supply and
HLCS activity in MCF-7 cells
The expression of c-Myc and COX-2 is inversely linked with biotin concentrations in
culture media. When MCF-7 cells were culture in biotin-defined media for 3 days, the
luciferase activity of c-Myc promoter reporter gene construct Luc-SNM (57) was
significantly improved in deficient cells, while decreased in sufficient cells, compared
with physiological cells (Fig.5). Following the treatment of biotin deficiency for 3 days,
MCF-7 cells showed a strong upregulation of COX-2 (Fig.6A) and c-Myc (Fig.6B)
mRNA expression compared with biotin treatment of physiological level. Treatment with
biotin-supplemented media for 3 days significantly decreased c-Myc (Fig.6B) expression
but had no effect on COX-2 (Fig.6A).
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HLCS activity is an important factor in repressing oncogene expression, particularly that
of COX-2. For example, the abundance of COX-2 mRNA was about 9-fold greater in
HLCS mutant WG2215 fibroblasts compared with wild-type controls (Fig. 7A). The
abundance of c-Myc mRNA followed the same trend but the increase in HLCS mutant
fibroblasts amounted to only 20% and did not reach a statistically significant level (P =
0.071) (Fig. 7B).
Mutagenesis studies suggest that biotinylation of K10 and K12, as opposed to
biotinylation of other residues, is a crucial event in the repression of oncogenes. When
MCF-7 cells were transfected with Flag constructs, the expression of COX-2 mRNA
decreased by >50% in cells transfected with the wild-type plasmid Flag-WT-MBP1
compared to cells transfected with the mutant plasmid MBP-1R10,12R (Fig. 8A). Not
surprisingly, COX-2 expression was intermediate in cells transfected with the Flagcontrol vector, because these cells presumably express wild-type MBP-1 from the two
endogenous alleles; in Flag-WT-MBP1 transfectants the plasmid provides additional
template, whereas in Flag-Mut-MBP1 transfectants mutant MBP-1 outcompetes the wilttype MBP-1 transcribed from the two endogenous alleles. The pattern was the same for cMyc (Fig. 8B) but the magnitude of effect was smaller than that observe for COX-2.
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Figure 1. MBP-1 is a novel biotin-binding protein in HEK293
cells. LC/MS/MS analysis suggests that K10 and K12 in MBP-1
are biotinylated.
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A

C

B

D

Figure 2. Generated anti-MBP-1bio specific against
biotinylated MBP-1. (A) Anti-MBP-1bio produced a strong signal
with peptide MBP-1bio in a dose-depend manner (1.5 ug, 0.75 ug
and 0.375 ug). (B) No signal produced by pre-immune serum. (C)
The signal intensity produced by 1.5 ug peptides, compared with
that produced by unbiotinylated MBP-1. (D) Extracts of MCF-7
cells after 3 days cultured in biotin-defined media, resolved by gel
electrophoresis and probed with anti-MBP-1bio and pre-immune
serum. MBP-1: synthetic unbiotinylated MBP-1 peptides; MBP-
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1bio: synthetic K10,K12-biotinylated MBP-1 peptides; BSAbio:
chemically biotinylated bovine serum albumin; H3K18bio:
synthetic peptides mimicking K18-biotinylated histone H3;
H4K8bio: synthetic peptides mimicking K8-biotinylated histones
H4.
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A

B

Figure 3. The abundance of MBP-1 biotinylation was directly
correlated with biotin-supply. (A) Abundance of

biotinylated MBP-1 in MCF-7 cells after 3 days of
culture in biotin-defined media. (B) Abundance of
biotinylated carboxylases in MCF-7 cells after 3 days of
culture in biotin-defined media.
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Figure 4. MBP-1 interacts with HLCS in vitro. Recombinant
GST-HLCS catalyzed the binding of biotin to recombinant HisMBP-1, judged by streptavidin blots.
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Figure 5. Biotin-supply regulates c-Myc promoter activity in
MCF-7 cells. Luciferase activity of c-Myc promoter reporter
construct in MCF-7 cells cultured in biotin-defined media,
normalized by beta-galactosidase activity. a,bBars not sharing the
same letter are significantly different; P< 0.05; N=3.
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A

B

Figure 6. Biotin-supply regulates COX-2 and c-Myc in MCF-7
cells. Expression of COX-2 (A) and c-Myc (B) in MCF-7 cells
after 3 days of culture in biotin-defined media.a,b,cBars not sharing
the same letter are significantly different; P< 0.05; N=3.
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B

Figure 7. The biotin-ligase activity of HLCS is required for
suppressor activity of MBP-1 on COX-2 and c-Myc. Expression
of COX-2 (A) and c-Myc (B). a,bBars not sharing the same letter
are significantly different; P < 0.05; N=3.
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A

B

Figure 8. The repressor ability of MBP-1 was inhibited when
the MBP-1 lacking biotinylation sites K10 and K12.
Overexpression of wild type MBP-1 decreased COX-2 (A) and cMyc (B) expression. However, the abundance of COX-2 (A) and
c-Myc (B) were upregulated in MCF-7 cells overexpressing mutant
MBP-1 compared with MCF-7 cells overexpressing Flag-WTMBP1 (N=1 with three technical replicates).
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Discussion
The novelty of this study comes from the following points: 1）this is the first report of
c-Myc promoter binding protein (MBP-1) biotinylation in the human proteome; 2) HLCS
is the sole enzyme responses for catalyzing covalent binding of biotin to MBP-1, in
addition to HSP72, carboxylases and histones (16, 52, 60); 3) K10 and K12 residues
located in the N-terminal functional domain of MBP-1 are the targets of biotinylation (31,
48).
Importantly, we showed that biotinylation of MBP-1 depends on biotin supply. We also
provided the evidences that the abundance of MBP-1 targets c-Myc (34) and COX-2 (29),
oncogenes strongly associate with tumorigenesis and metastasis of breast cancer (41, 61,
62), can be regulated by biotin supply as well as in an HLCS-mediated manner.
Combined with these observations, this study may provide insights epigenetic
explanations of observations in our Bal b/c wild type mice biotin feeding studies, which
suggests that biotin-deficient induced a ~100% increase in percentage of mice carry
multiple tumors or the percentage of tumors presenting as multiple (Fig. 8). Given the
observations of biotin deficiency increasing oncogenes c-Myc and COX-2 expression in
vitro in this study, the increase of tumor load in biotin-deficient mice may be induced by
improving expression of oncogenes, unregulated by lacking of MBP-1 biotinylation.
Several uncertainties needed to be considered: 1) no human biotin requirements or foods
intake recommendations have been estimated; 2) currently, there is no reliable marker in
quantification of biotin status in human (63). Therefore, it is uncertain whether the biotin-

33
dependent regulation of mechanisms contributing to tumorigenesis and is significant in
western population. However, marginal biotin deficiency is common in pregnant women,
which may cause human birth defects(64); biotin deficiency and low serum biotinidase
activity can be induced by Valproic acid (VPA) treatment in human (65, 66). More
importantly, several population-based studies reported that a substantial proportion of
cancer patients treated with chemotherapy and radiation therapy have deficiencies of
multiple vitamins (67-70), which suggests that biotin deficiency may be common in
cancer patients with chemotherapy and radiation treatment.
Collectively, the covalent binding of biotin to MBP-1 is strongly associated with
oncogenes expression. Future studies including biotin status in cancer patients, breast
cancer risk in HLCS knock-out mice (conditional knock-out project in progress) will be
conducted to determine whether biotin deficiency increases metastasis, development of
new tumors or both in breast cancer.

34

A

B

Figure 9. Tumor load of Bal b/c wild type mice in biotinfeeding study. Both percentage of mice carry multiple tumors (A)
and percentage of mice carrying tumors presenting as multiple (B)
were ~100% increase in low-biotin-feeding mice compared with
mice fed with physiological and high levels of biotin in diet.
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APPENDIX
List of Primers
Table 1 Human primers used for qRT-PCR
Gene
c-Myc
COX-2
HLCS
GAPDH

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Primer Sequence (5’-3’)
TTCGGGTAGTGGAAAACCAG
CAGCAGCTCGAATTTCTTCC
ACAGGCTTCCATTGACCAG
TCACCATAGAGTGCTTCCAAC
TGAGACCTGATCCTTAACTTCC
ATGGAAGATAGACTCCACAT
TCCACTGGCGTCTTCACC
GGCAGAGATGATGACCCTTT

Ta (oC)
50
50
50
50

c-Myc= v-Myc Avian Myelocytomatosis Viral Oncogene Homolog (NCBI Reference
Sequence: NM_002467.4); COX-2= Cyclooxygenase 2 (NCBI Reference Sequence:
NM_000963.2); HLCS= Holocarboxylase Synthetase (NCBI Reference Sequence:
NM_000411.6); GAPDH= Glyceraldehyde-3-phosphate Dehydrogenase (NCBI
Reference Sequence: NM_002046.4).

Table 2 Human primers used for PCR amplification and Sitedirected mutagenesis (SDM)
Plasmid
His-MBP1
Flag-MBP-WT
MBP-1R10,R12

Forward
Reverse
Forward
Reverse
Forward
Reverse

Primer Sequence (5’-3’)
TTCGGGTAGTGGAAAACCAG
CAGCAGCTCGAATTTCTTCC
ACAGGCTTCCATTGACCAG
TCACCATAGAGTGCTTCCAAC
ACAGGCTTCCATTGACCAG
TCACCATAGAGTGCTTCCAAC

Restriction
enzyme sites
Bamh1
Sal1
EcoRI
KpnI
EcoRI
KpnI

Ta (oC)
58
55.5
55.5
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Table 2 Primers used Site-directed mutagenesis (SDM)
Plasmid
ENO1_Mut

Forward
Reverse

Primer Sequence (5’-3’)
ATG GAA CAG AAA ATA GAT CTA GGT TTG GTG CGA ACG C
GCG TTC GCA CCA AAC CTA GAT CTA TTT TCT GTT CCA T

Annotation: IEMDGTENKSK mutated to IEMDGTENRSR

